Author(s)Healy BC, Glanz BI, Zurawski JD, Mazzola M, Chitnis T, Weiner HL. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta, glatiramer acetate. J Neurol Sci.
LA JOLLA, CA -- May 13, 2015 -- Interferon proteins are normally considered virus-fighters, but scientists at The Scripps Research Institute (TSRI) have found evidence that one of them, interferon ...
NEW YORK CITY, Oct. 28, 2020 (GLOBE NEWSWIRE) -- UPDATE: BetterLife CEO Highlights Crucial Difference Between the Company’s Interferon Alpha 2b and Synairgen PLC’s Interferon Beta The Chief Executive ...
Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an α 4 integrin antagonist, appeared to be safe ...
A study published in this week’s issue of THE LANCET suggests that high-dose interferon beta-1b administered every other day is more effective than interferon beta-1a once a week for people with ...
Data reviewed in this article demonstrate that both interferon-ß-1a (IFNß-1a) and interferon-ß-1b (IFNß-1b) show a dose-response relationship in multiple sclerosis at current clinical doses. Moreover, ...
October 26, 2007 (Prague, Czech Republic) — Results of a head-to-head clinical trial of glatiramer acetate (Copaxone, Teva Pharmaceutical Industries) and interferon beta-1a (Rebif , Merck Serono) in ...
Roche's ocrelizumab significantly reduced both relapses and disability progression versus interferon beta-1a (Rebif®) in two Phase III studies in multiple sclerosis Studies showed superiority on ...
EXTON, Pa.--(BUSINESS WIRE)--Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has secured an exclusive option and license agreement utilizing PolyTherics' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results